Vax2Muc consortium discusses research progress in Lisbon

Vax2Muc partners met in Lisbon from 16 to 17 September to discuss project progress, brainstorm, and plan future activities.

The scientists involved in the Vax2Muc project met in Portugal following the XXXVIIth Workshop of the European Helicobacter and Microbiota Study Group, to share updates from their work in developing next-generation vaccines to combat infections in the mucosal membrane of the intestinal tract. During the meeting hosted by the project partner, the Faculty of Pharmacy at the University of Lisbon, the researchers had the chance to reflect on progress so far, participate in fruitful discussions, and present the next steps in each partner’s plans.

Reflecting on the meeting, Vax2Muc coordinator Dr Markus Gerhard praised the “intense and constructive interaction between partners. There is a lot of direct exchange at all levels, between principal investigators and also between the post-docs and students, which accelerates the progress and contributes to technological and scientific transfer.”

Continuous collaboration and exchange of ideas are critical in a project that aims to find innovative solutions to overcome antimicrobial resistance of gastrointestinal mucosal pathogens. Following this latest meeting, partners are confident that their work is on track.

Results will soon emerge through current and planned in vivo studies, bringing the project to the next level.

Vax2Muc is funded by the Horizon Europe research and innovation programme and runs for five years until June 2028.